Gemifloxacin for community-acquired pneumonia.
BACKGROUND
Newer fluoroquinolones have become an important therapeutic choice in the treatment of community-acquired pneumonia (CAP). Gemifloxacin is one of the newest members of this class of antibiotics and has performed favourably in this indication.


OBJECTIVE
To analyse the microbiological activity, pharmacokinetic/pharmacodynamic properties and clinical activity of gemifloxacin in CAP, as well as the safety reported in controlled clinical studies.


METHODS
Literature research of English publications in the last 10 years addressing all aspects of gemifloxacin in CAP.


CONCLUSIONS
Gemifloxacin is microbiologically the most active fluoroquinolone against Streptococcus pneumoniae--the leading pathogen of CAP. In several comparative studies gemifloxacin was highly effective and well tolerated in the treatment of mild-to-moderate severe CAP.
Lode
Hartmut M
HM
RCMS, Hohenzollerndamm 2, Ecke Bundesallee, D-10717 Berlin-Wilmersdorf, Germany. haloheck@zedat.fu-berlin.de
Schmidt-Ionas
Malina
M
Stahlmann
Ralf
R
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017714:Community-Acquired Infections; D024841:Fluoroquinolones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000077735:Gemifloxacin; D006801:Humans; D009287:Naphthyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D000077735:Gemifloxacin